相关实验视频
Updated: Jun 7, 2025
08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
7.2K
骨髓瘤免疫微环境重塑和C1QBP驱动的耐药性空间时间进化过程通过单细胞多维分析破译
Xin Wu1, Ning Tang2, Qiangqiang Zhao3,4
1Department of Spine Surgery, Third Xiangya Hospital Central South University Changsha Hunan China.
Bioengineering & translational medicine
|November 18, 2024
概括
这项研究表明,C1QBP基因与骨髓瘤 (OS) 存活率差相关,并促进瘤生长和耐药性. 准C1QBP可能为OS患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 瘤免疫微环境显著影响癌症的进展,包括骨髓瘤 (OS).
- 了解OS启动和进展机制对于开发有效的治疗方法至关重要.
研究的目的:
- 通过使用集成的单细胞和散装RNA测序,全面地绘制OS瘤免疫微环境.
- 确定与OS进展和患者存活相关的关键基因.
主要方法:
- 合成多个单细胞RNA测序数据集用于OS.
- 与大量RNA测序数据的整合.
- 生物信息分析以确定基因表达模式和相关性.
主要成果:
- 确定了脂肪酸代谢基因C1QBP的高表达与OS患者的生存率降低之间的显著相关性.
- C1QBP增强了OS细胞的增殖,迁移,入侵和对西斯的抵抗力.
- C1QBP可能会促进M2和M3巨细胞的两极分化.
结论:
- C1QBP在骨髓瘤进展和化学抵抗方面发挥着关键作用.
- C1QBP是一种潜在的新型治疗点,用于调节OS和克服治疗耐药性.
更多相关视频
11:15A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
10.2K
07:44Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
Published on: March 12, 2018
10.1K
相关概念视频
02:30Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K